{"version":"1.0","provider_name":"IFPMA","provider_url":"https:\/\/www.ifpma.org","title":"How the COVID-19 pandemic sparked innovation in clinical trials: considerations for the future | IFPMA","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"bQZJIqG8Pz\"><a href=\"https:\/\/www.ifpma.org\/insights\/how-the-covid-19-pandemic-sparked-innovation-in-clinical-trials-considerations-for-the-future-2\/\">How the COVID-19 pandemic sparked innovation in clinical trials: considerations for the future<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.ifpma.org\/insights\/how-the-covid-19-pandemic-sparked-innovation-in-clinical-trials-considerations-for-the-future-2\/embed\/#?secret=bQZJIqG8Pz\" width=\"600\" height=\"338\" title=\"&#8220;How the COVID-19 pandemic sparked innovation in clinical trials: considerations for the future&#8221; &#8212; IFPMA\" data-secret=\"bQZJIqG8Pz\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/06\/iStock-1348321039.jpg","thumbnail_width":2104,"thumbnail_height":1425,"description":"The COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Sarah Adam explains what we can learn from this experience when it comes to clinical trials."}